Regulatory affairs managers at pharmaceutical sponsors use this agent when developing or revising a Paediatric Investigation Plan for EMA submission or a Paediatric Study Plan for FDA, particularly when responding to an initial EMA PDCO opinion that has requested modifications. The complexity of age-banded study designs, formulation requirements, and extrapolation justifications makes these documents highly specialised.